п»їXalkori (Non-Small Cell Lung Cancer) - Outlook and Market Analysis to 2022 On 25th Summer 2014
JSB Researching the market added fresh report " Xalkori (Non-Small Cell Lung Cancer) -- Forecast and Market Evaluation to 2022" in its retail store Non-Small Cellular Lung Tumor (NSCLC) is considered the most common lung cancer, and the second-most prevalent cancer in men and women. Traditionally, the treatment paradigm has focused around chemotherapy. However , the launch of targeted therapies for individuals with particular biomarkers has started to come apart the NSCLC treatment panorama into smaller sized niche patient populations. In the forecast period, this craze will continue with the start of multiple new medications in several fresh drug classes to address the high unmet need between NSCLC individuals, and provide new treatment options pertaining to previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident instances of the disease will be main drivers of growth inside the major marketplaces. В Browse Total Report snabel-a http://www.jsbmarketresearch.com/healthcare-medical/r-Xalkori-Non-Small-Cell-Lung-Cancer-Forecast-and-Market-Analysis-to-2022-114975 Pfizers twice-daily dental tablet, Xalkori, is indicated in the US pertaining to the treatment of ALK-positive NSCLC sufferers, as dependant on an Medical grade companion diagnostic. Xalkori has brought conditional advertising authorization in the EU use with ALK-positive individuals, and perseverance of ALK status is required by virtually any appropriate means.
-- Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview around the competitive panorama. - Detailed information on Xalkori including item description, basic safety and efficacy profiles and a SWOT examination. - Revenue forecast pertaining to Xalkori intended for the top nine countries by 2012 to 2022. -- Sales information covered intended for the US, England, Germany, Italia, Spain, great britain, Japan, India and Cina.
Reasons to get
Bibliography: Table 7: Xalkori SWOT Analysis, 2013 37
Table 8: Global Sales Predictions ($m) for Xalkori, 2012-2022 38